The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype

被引:54
作者
Iacopetta, B [1 ]
Grieu, F
Joseph, D
机构
[1] Univ Western Australia, Sch Surg & Pathol, Nedlands, WA 6009, Australia
[2] Sir Charles Gairdner Hosp, Dept Radiat Oncol, Nedlands, WA 6009, Australia
关键词
interleukin-6; polymorphism; breast cancer; prognosis;
D O I
10.1038/sj.bjc.6601545
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Serum and tissue levels of interleukin-6 (IL-6) have been implicated in the biological phenotype of breast carcinoma. A common G/C polymorphism at position -174 of the IL-6 promoter can influence the expression level of this gene. We therefore investigated for associations between this polymorphism and various phenotypic features in a series of 256 breast cancers. Individuals who were homozygous for the C allele (n = 55) were more likely to have higher-grade tumours (P = 0.039) with ductal histology (P = 0.030) compared to those harbouring at least one wild-type G allele (n = 201). Homozygosity for the C allele was also associated with significantly worse overall survival (P = 0.031). We conclude that the -174 C allele of IL-6 is associated with a more aggressive breast cancer phenotype.
引用
收藏
页码:419 / 422
页数:4
相关论文
共 28 条
[1]   Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients [J].
Bachelot, T ;
Ray-Coquard, I ;
Menetrier-Caux, C ;
Rastkha, M ;
Duc, A ;
Blay, JY .
BRITISH JOURNAL OF CANCER, 2003, 88 (11) :1721-1726
[2]  
Basolo F, 1998, CLIN CANCER RES, V4, P381
[3]   NORMAL BREAST EPITHELIAL-CELLS PRODUCE INTERLEUKIN-6 AND INTERLEUKIN-8 TOGETHER WITH TUMOR-NECROSIS-FACTOR - DEFECTIVE IL6 EXPRESSION IN MAMMARY-CARCINOMA [J].
BASOLO, F ;
CONALDI, PG ;
FIORE, L ;
CALVO, S ;
TONIOLO, A .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (06) :926-930
[4]  
Basolo F, 1996, CANCER RES, V56, P3118
[5]   Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer [J].
Belluco, C ;
Nitti, D ;
Frantz, M ;
Toppan, P ;
Basso, D ;
Plebani, M ;
Lise, M ;
Jessup, JM .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (02) :133-138
[6]  
Belluco C, 2003, CLIN CANCER RES, V9, P2173
[7]   SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER [J].
BEREK, JS ;
CHUNG, C ;
KALDI, K ;
WATSON, JM ;
KNOX, RM ;
MARTINEZMAZA, O .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (04) :1038-1043
[8]   Association of an allelic variant of interleukin-6 with subclinical carotid atherosclerosis in an Australian community population [J].
Chapman, CML ;
Beilby, JP ;
Humphries, SE ;
Palmer, LJ ;
Thompson, PL ;
Hung, J .
EUROPEAN HEART JOURNAL, 2003, 24 (16) :1494-1499
[9]   Interleukin-6 gene polymorphism and insulin sensitivity [J].
Fernández-Real, JM ;
Broch, M ;
Vendrell, J ;
Gutiérrez, C ;
Casamitjana, R ;
Pugeat, M ;
Richart, C ;
Ricart, W .
DIABETES, 2000, 49 (03) :517-520
[10]   The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis [J].
Fishman, D ;
Faulds, G ;
Jeffery, R ;
Mohamed-Ali, V ;
Yudkin, JS ;
Humphries, S ;
Woo, P .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (07) :1369-1376